The role of chemotherapy in the management of mesothelioma

Julian R. Molina; Alex A. Adjei

doi:10.1007/3-540-31040-1_44

The role of chemotherapy in the management of mesothelioma

Julian R. Molina, Alex A. Adjei

Medical Oncology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

44.6 Conclusions: Several chemotherapy agents have shown minor activity in MPM. Most of the studies supporting their use as single agents or in combination are misleading because of the sample size, lack of uniform measures of response, and lack of reproducibility. However, the combination of cisplatin with pemetrexed has demonstrated improved survival in phase III studies and is now considered standard therapy for mesothelioma.

Original language	English (US)
Title of host publication	Tumors of the Chest
Subtitle of host publication	Biology, Diagnosis and Management
Publisher	Springer Berlin Heidelberg
Pages	515-524
Number of pages	10
ISBN (Print)	6293603618, 9783540310396
DOIs	https://doi.org/10.1007/3-540-31040-1_44
State	Published - 2006

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/3-540-31040-1_44

Cite this

@inbook{cb72603319e745e39af580d4d9329762,

title = "The role of chemotherapy in the management of mesothelioma",

abstract = "44.6 Conclusions: Several chemotherapy agents have shown minor activity in MPM. Most of the studies supporting their use as single agents or in combination are misleading because of the sample size, lack of uniform measures of response, and lack of reproducibility. However, the combination of cisplatin with pemetrexed has demonstrated improved survival in phase III studies and is now considered standard therapy for mesothelioma.",

author = "Molina, {Julian R.} and Adjei, {Alex A.}",

year = "2006",

doi = "10.1007/3-540-31040-1_44",

language = "English (US)",

isbn = "6293603618",

pages = "515--524",

booktitle = "Tumors of the Chest",

publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - The role of chemotherapy in the management of mesothelioma

AU - Molina, Julian R.

AU - Adjei, Alex A.

PY - 2006

Y1 - 2006

N2 - 44.6 Conclusions: Several chemotherapy agents have shown minor activity in MPM. Most of the studies supporting their use as single agents or in combination are misleading because of the sample size, lack of uniform measures of response, and lack of reproducibility. However, the combination of cisplatin with pemetrexed has demonstrated improved survival in phase III studies and is now considered standard therapy for mesothelioma.

AB - 44.6 Conclusions: Several chemotherapy agents have shown minor activity in MPM. Most of the studies supporting their use as single agents or in combination are misleading because of the sample size, lack of uniform measures of response, and lack of reproducibility. However, the combination of cisplatin with pemetrexed has demonstrated improved survival in phase III studies and is now considered standard therapy for mesothelioma.

UR - http://www.scopus.com/inward/record.url?scp=84892825846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892825846&partnerID=8YFLogxK

U2 - 10.1007/3-540-31040-1_44

DO - 10.1007/3-540-31040-1_44

M3 - Chapter

AN - SCOPUS:84892825846

SN - 6293603618

SN - 9783540310396

SP - 515

EP - 524

BT - Tumors of the Chest

PB - Springer Berlin Heidelberg

ER -

The role of chemotherapy in the management of mesothelioma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this